Yantao He
Indiana University
10 Papers
29 Citations
Yantao He is an academic researcher from Indiana University. The author has contributed to research in topics: Protein tyrosine phosphatase & Autoimmunity. The author has an hindex of 8, co-authored 10 publications. Previous affiliations of Yantao He include Indiana University – Purdue University Indianapolis.
Chat about Author
Papers
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
Xian Zhang,Yantao He,Sijiu Liu,Zhi-Hong Yu,Zhong Xing Jiang,Zhenyun Yang,Yuanshu Dong,Sarah C. Nabinger,Li Wu,Andrea M. Gunawan,Lina Wang,Rebecca J. Chan,Zhong Yin Zhang +12 more
TL;DR: A salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity led to the identification of a SHP2 inhibitor II-B08 (compound 9) with highly efficacious cellular activity, providing supporting evidence that chemical inhibition ofSHP2 may be therapeutically useful for anticancer and antileukemia treatment.
226
Cutting Edge: The PTPN22 Allelic Variant Associated with Autoimmunity Impairs B Cell Signaling
Adrian F. Arechiga,Tania Habib,Yantao He,Xian Zhang,Zhong Yin Zhang,Andrew Funk,Jane H. Buckner +6 more
TL;DR: It is shown that B cell signal transduction is impaired in individuals who express the PTPN22 1858T variant, which is suggested to alter BCR signaling and implicate B cells in the mechanism by which the P TPN22 2018T variant contributes to autoimmunity.
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases
TL;DR: The identification of a bidentate salicylic acid-based Lyp inhibitor I-C11 with excellent cellular efficacy is reported and established a mechanism by which PKC could attenuate the cellular function of Lyp, thereby augmenting T cell activation.
159
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors
Rongjun He,Zhi-Hong Yu,Ruo-Yu Zhang,Li Wu,Andrea M. Gunawan,Brandon S. Lane,Joong Sup Shim,Li-Fan Zeng,Yantao He,Lan Chen,Clark D. Wells,Jun O. Liu,Zhong Yin Zhang +12 more
TL;DR: A strategy to explore the existing drug space for previously unknown PTP inhibitory activities led to the discovery of cefsulodin as an inhibitor of SHP2, an oncogenic phosphatase in the PTP family.
50
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors
Rongjun He,Zhi-Hong Yu,Ruo-Yu Zhang,Li Wu,Andrea M. Gunawan,Brandon S. Lane,Joong Sup Shim,Li-Fan Zeng,Yantao He,Lan Chen,Clark D. Wells,Jun O. Liu,Zhong Yin Zhang +12 more
- 09 Jul 2015
TL;DR: In this article, the authors describe a strategy to explore the existing drug space for previously unknown protein tyrosine phosphatases (PTPs) inhibitory activities, which led to the discovery of cefsulodin as an inhibitor of SHP2, an oncogenic phosphatase in the PTP family.
24